Join the Myasthenia Gravis group to help and get support from people like you.
Myasthenia Gravis News
FDA Approves Zilbrysq for Generalized Myasthenia Gravis
TUESDAY, Oct. 24, 2023 (HealthDay News) -- The U.S. Food and Drug Administration has approved Zilbrysq (zilucoplan) for the treatment of adults with generalized myasthenia gravis. Zilbrysq is a target...
FDA Approves Zilbrysq (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis
ATLANTA, Oct. 17, 2023 /PRNewswire/ – UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that Zilbrysq® (zilucoplan) has been approved by the U.S. Food and Drug ...
FDA Approves Rystiggo (rozanolixizumab-noli) for the Treatment of Adults with Generalized Myasthenia Gravis
Brussels (Belgium) June 27 2023 – UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced Rystiggo® (rozanolixizumab-noli)* has been approved by the U.S. Food and Drug Ad...
FDA Approves Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for Subcutaneous Use in Generalized Myasthenia Gravis
SAN DIEGO, June 20, 2023 /PRNewswire/ – Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received U.S. Food and Drug Administration (FDA) approval for Vyvgart...
Ultomiris Approved in the US for Adults with Generalised Myasthenia Gravis
First and only long-acting C5 complement inhibitor to demonstrate clinical improvement in patients with generalised myasthenia gravis Ultomiris showed early effect and lasting improvement in...
FDA Approves Vyvgart (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis
Breda, the Netherlands—Dec. 17, 2021 - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and c...
FDA Approves Soliris (eculizumab) for the Treatment of Patients with Generalized Myasthenia Gravis (GMG)
NEW HAVEN, Conn.--(BUSINESS WIRE) October 23, 2017 --Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the U.S. Food and Drug Administration (FDA) has approved Soliris (eculizumab) as...
Ask a question
To post your own question to this support group, sign in or create an account.